CHOCS
Food supplement declared in France, decision dated 7 November 2026
CHOCS is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.
- Brand
- not provided
- Food business operator placing the product on the market
- SANTISLAB FRANCE SAS
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Autre : stick buvable
- Daily dose
- 1 à 3 sticks buvables
- Directions for use
- Prendre 1 à 3 sticks buvables par jour.
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (moins de 18 ans), Femmes allaitantes, Autre : Inconfort après chocs, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous anticoagulants, Utilisation prolongée, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
- Objectives stated by the manufacturer (these are not authorised claims)
- Autre : Inconfort après chocs
Declaration 378211, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Bellis perennis L. | Fleur | Extrait fluide aqueux | 6,249 mg |
| Hamamelis virginiana L. | Feuille | Extrait fluide aqueux | 6,249 mg |
| Tanacetum parthenium (L.) Sch.Bip. | Parties aériennes | Extrait sec hydroalcoolique | 83.1 mg |
| Helichrysum italicum (Roth.) G. Don. | Essence (sommités fleuries) | Distillation | 1.65 mg |
Additives
E955, E202, E211, E330, E415, E422
Other ingredients
eau, sirop de blé
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé en cas d'allergie croisée connue, en particulier à la famille des Asteraceae. Ne pas utiliser en cas de traitement anticoagulant ou antiagrégant. Demander conseil à un professionnel de santé, notamment en cas d'antécédents épileptiques ou de convulsions. Pas d'usage prolongé, ne pas dépasser 2 semaines de prise.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Hamamelis virginiana L.
Read the warning, when it applies and the studies cited
WITCH HAZEL - HAMAMELIS VIRGINIANA Buccal and Oromucosal
Route of administration: Buccal Oromucosal
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 February 2026
WITCH HAZEL - HAMAMELIS VIRGINIANA Ophthalmic
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist (for) more than 2 days (EMA 2009).
Sources cited by Health Canada (1)
- EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience eye pain, changes in vision, continued redness, or irritation of the eye (EMA 2009).
Sources cited by Health Canada (1)
- EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf
Health Canada monograph dated 27 February 2026
WITCH HAZEL -HAMAMELIS VIRGINIANA Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Gardner and McGuffin 2013; ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).
Sources cited by Health Canada (4)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
Health Canada monograph dated 27 February 2026
WITCH HAZEL - HAMAMELIS VIRGINIANA Topical
Cautions and warnings
Condition of application: All products.
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Applies to products for use on minor wounds/burns/bruises/irritations/inflammations or on hemorrhoids.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen, last (for) more than 7 days.
Applies to products for use on varicose veins.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Applies to products for use on minor wounds/burns/bruises/irritations/inflammations.
Do not use on deep or puncture wounds, animal bites or serious burns.
Known adverse reactions
Condition of application: All products.
Stop use if a skin rash occurs (ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
Applies to products for use on hemorrhoids.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience bleeding.
- Tanacetum parthenium (L.) Sch.Bip.
Read the warning, when it applies and the studies cited
FEVERFEW - TANACETUM PARTHENIUM
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).
Sources cited by Health Canada (2)
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).
Sources cited by Health Canada (1)
- Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.
Contraindications
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.
Do not use if you are pregnant or breastfeeding (EMA 2020).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).
Sources cited by Health Canada (2)
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).
Sources cited by Health Canada (3)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Chocs Vitasantis, declared in 2021 : different composition: 1 ingredient(s) added, 2 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.